US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors

Mumbai (Maharashtra) [India], January 3 (ANI/PRNewswire): Datar Cancer Genetics announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra-Glio', a blood test to help in the diagnosis of brain tumors

Related Keywords

United States ,Mumbai ,Maharashtra ,India ,United Kingdom ,London ,City Of ,Kevin Oneill ,Sewanti Limaye ,Darshana Patil ,Brain Tumor Research Campaign ,Drug Administration ,Imperial College ,Oncology Research ,Sir Hn Reliance Foundation Hospital ,Breakthrough Devices Program ,European Union ,Datar Cancer Genetics ,Breakthrough Device Designation ,Breakthrough Device ,Consultant Neurosurgeon ,Principal Investigator ,Brain Tumor Research Charity ,Precision Oncology ,Foundation Hospital ,Medical Director ,Breakthrough Designation ,Cancer Genetics ,Us ,Fda ,Migrants ,Breakthrough ,Resignation ,Or ,Flood ,Pest ,O ,Help ,Diagnose ,Inaccessible ,Rain ,Rumors ,News ,Ews India ,